Chemours Company Dossier - Source-backed chat

Chemours Company

CCNYSE

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)1.28

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $13.48Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2B

Enterprise Value $5.2B

Shares Outstanding 151.2M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

Last ex-dividend14 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Chemours Co presents a highly bifurcated investment profile. On one hand, its Thermal & Specialized Solutions (TSS) segment is a powerful growth engine, driven by secular regulatory tailwinds and rapid adoption of low-GWP Opteon™ refrigerants. On the other hand, the company continues to grapple with cyclical headwinds and operational disruptions in its Titanium Technologies (TT) and Advanced Performance Materials (APM) segments, alongside a heavy debt load and persistent legacy PFAS liabilities. While the 'Pathway to Thrive' strategy outlines a clear route to operational excellence and deleveraging, the current valuation adequately reflects near-term recovery prospects, making a Hold rating appropriate.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$19.78

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.0020%

Persistent operational setbacks, such as further production outages or prolonged weakness in cyclical end markets, drag down APM and TT margins. Deleveraging efforts are stymied by higher-than-expected legacy PFAS litigation payouts or restructuring costs, keeping net leverage elevated and putting pressure on the company's credit profile.

Base CaseCentral scenario

$19.7855%

Matches the consensus mean

TSS continues to deliver steady double-digit growth, offsetting near-term softness in TT and APM. The company successfully executes its cost-saving initiatives, achieving its target of net leverage below 3.8x by year-end 2026. Cyclical recovery in the titanium dioxide market begins to take shape in late 2026, supporting a gradual re-rating of the stock.

Bull CaseUpside scenario

$24.0025%

Accelerated global adoption of Opteon™ refrigerants and rapid commercialization of two-phase liquid cooling solutions for AI data centers drive outsized TSS growth. Normalizing operations at the Washington Works facility and successful TiO2 price increases lead to a swift margin recovery in APM and TT. Strong cash generation enables the company to deleverage ahead of schedule, bringing net leverage well below 3.0x.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Market leadership in low-GWP refrigerants (Opteon™) with strong regulatory tailwinds.
Exposure to high-growth secular trends including AI data center cooling, semiconductors, and clean hydrogen.
Clear corporate strategy ('Pathway to Thrive') focused on cost reduction, portfolio optimization, and deleveraging.

Key Investment Risks

Significant overhang from legacy PFAS and environmental litigation liabilities.
High leverage with elevated net debt, exposing the company to financing costs and execution risks.
Cyclical exposure and operational volatility in the Titanium Technologies and Advanced Performance Materials segments.

Thesis Invalidation Triggers

Failure to achieve the guided Q2 2026 consolidated Adjusted EBITDA of $220 million to $250 million.
Inability to bring the net leverage ratio below 3.8x Adjusted EBITDA by year-end 2026.
Unexpected material escalation in PFAS-related liabilities or remediation costs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.